Navigation Links
VIVUS Reports Second Quarter and First Six Months 2011 Financial Results
Date:8/1/2011

ld be well positioned to assist ED patients looking for a fast treatment alternative," stated Leland Wilson, chief executive officer of VIVUS.

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead investigational product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. VIVUS received a Complete Response Letter, or CRL, to the initial QNEXA NDA on October 28, 2010. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS has submitted an NDA for avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.

Note to Investors As previously announced, VIVUS will hold a conference call and an audio webcast to discuss the second quarter financial results today, August 1, 2011, beginning at 1:30 p.m. Pacific Time. Investors can listen to this call by dialing 1-877-359-2916 and outside the U.S. 1-224-357-2386. A webcast replay will be available for 30 days and can be accessed at http://ir.vivus.com/.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the timing and substance of our response to the FDA's requests from the End of Review meeting; our re
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results
2. VIVUS to Present at Three Upcoming Investor Conferences in March
3. VIVUS Provides Regulatory Update on QNEXA NDA
4. VIVUS to Present at the 2011 JP Morgan Healthcare Conference
5. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
6. VIVUS to Present at Two Upcoming Investor Conferences
7. VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
8. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
9. VIVUS Announces Sale of MUSE Assets to Meda
10. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
11. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013  Inhibikase Therapeutics, Inc., an emerging leader ... will present new results on its antiviral program ... by the PML Consortium (composed of Pfizer, Bristol-Meyers ... is the causative agent of Progressive Multifocal Leukoencephalopathy ... an extended release formulation, can clear JC polyomavirus ...
(Date:5/23/2013)... 23, 2013  Echo Pharma Acquisition Limited ("Royalty Pharma") ... the Acceptance Threshold from 90 percent to 50 percent ... in accordance with the terms of the Revised Offer ... Under the terms of the Increased Offer, ... ELN ) for $12.50 per share in cash. ...
(Date:5/23/2013)... , May 23, 2013   BioLife Solutions , ... proprietary clinical grade hypothermic storage and ... contract aseptic media manufacturer , today announced its ... Regenerative Medicine Congress 2013 this week in ... ) Dr. Aby J. Mathew, BioLife,s Senior ...
Breaking Medicine Technology:Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 2Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 2Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 3Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 5Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 6Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 7Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 8Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 9Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 10BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 2BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 3
... /PRNewswire-iReach/ -- ShelfX, provider of revolutionary ... of the Vending Fridge. As the next-generation vending ... simple QR code scanner from their mobile phone ... refrigerated products. The Vending Fridge can be conveniently ...
... Wolf Medical Instruments Corporation celebrates 40 years of ... that spare patients the costs and recovery time ... http://photos.prnewswire.com/prnh/20120426/CG95191LOGO ) Richard Wolf endoscopes ... visualize and access elusive sites of disease or ...
Cached Medicine Technology:ShelfX Releases A Fridge That Knows What You Took 2Richard Wolf Medical Instruments Corporation: 40 Years of Innovation 2
(Date:5/23/2013)... San Francisco, CA (PRWEB) May 23, 2013 ... community safety outreach program being tackled by the Safe ... its second Fullpower personal safety workshop for ... develops and teaches personal safety skills programs for people ... been telling us their experiences with street harassment for ...
(Date:5/23/2013)... Lake City, Utah (PRWEB) May 23, 2013 ... Chevreau, PhD, R.D., published an article today on Tatalou.com ... an illness-free vacation. , The article, titled “ How ... why it’s important to carry hand sanitizer, when it’s ... to watch out for seafood, the importance of staying ...
(Date:5/23/2013)... 23, 2013 Dimensional Insight, a ... announced today that Paul Comras, director of ... at the 2013 International Medical Users Software Exchange ... & Revenue Visibility from Your General Ledger.” The ... from 2:30-3:25 p.m. in Azalea 1 at the ...
(Date:5/23/2013)... Alexandria, VA (PRWEB) May 23, 2013 Memorial ... start of the summer season for many Americans. Across the ... the long weekend. NHPCO encourages Americans to reach out to ... in military service. , As the nation marks Memorial Day ... Serious injuries and the untimely deaths of brave service men ...
(Date:5/23/2013)... To better serve the architecture ... pleased to announce the release of its new ... space division products. Provided by Koroseal, a leader ... patterns and colors represent a sophisticated response to ... a team of Koroseal experts, Modernfold reviewed hundreds ...
Breaking Medicine News(10 mins):Health News:San Francisco Tenderloin Women Say “No!” to Street Harassment: Safe Passage Sponsors Kidpower Adult Safety Skills Workshops and Resources 2Health News:San Francisco Tenderloin Women Say “No!” to Street Harassment: Safe Passage Sponsors Kidpower Adult Safety Skills Workshops and Resources 3Health News:San Francisco Tenderloin Women Say “No!” to Street Harassment: Safe Passage Sponsors Kidpower Adult Safety Skills Workshops and Resources 4Health News:How to Stay Healthy While Traveling 2Health News:Dimensional Insight to Demonstrate How Hospitals Can Use Business Intelligence within MEDITECH Environments at 2013 International MUSE Conference 2Health News:Memorial Day: Make it a Time of Remembrance and Support 2Health News:Memorial Day: Make it a Time of Remembrance and Support 3Health News:Modernfold Debuts New Colors and Patterns for Space Division Products 2
... treatment if they donate eggs for controversial cloning research.// ... for ‘egg sharing' so as to advance work on human ... this scheme and pass on their spare eggs to the ... by almost half. , ,The researcher team from ...
... of Agriculture have indicated the enhanced nutritive benefits of ... ,According to scientists, watermelons are a production ... the parent plant, which slows down once the melon ... 70 degrees, contained almost 40% of lycopene and 50 ...
... than with most modern antibiotics, according to a recent ... from the University of Bonn, Germany in collaboration with ... that medihoney is a very effective treatment for several ... infected with multi-resistant bacteria within a few weeks. ...
... and Channel 7 Indian Television network has raised many questions ... professionals. A cleaning up operation is long overdue to rejuvenate ... World Medical Association in 1949 - I ... of humanity …. I will practice my profession with conscience ...
... to an article that was published in the July 24 ... the JAMA/Archives journals, states that women who take// combination of ... have an increased risk of breast cancer. ... their normal levels of the testosterone hormone would be likely ...
... drug that is widely used in heart failure. Some ... is contraindicated. //However a new analysis shows that the ... heart failure. ,"Contrary to conventional wisdom, digitalis ... advances our understanding of both digitalis, the oldest known ...
Cached Medicine News:Health News:IVF Price To Be Reduced If Women Opt For Egg Sharing Scheme 2Health News:IVF Price To Be Reduced If Women Opt For Egg Sharing Scheme 3Health News:Maimed Conscience and Maimed Beggars (Medical Ethics in India) – Part 2Health News:Maimed Conscience and Maimed Beggars (Medical Ethics in India) – Part 3Health News:Maimed Conscience and Maimed Beggars (Medical Ethics in India) – Part 4Health News:Study Indicates An Increased Risk Of Breast Cancer In Women Undertaking Estrogen and Testosterone Therapy 2Health News:Digitalis Could Be Safe In Diastolic Heart Failure 2Health News:Digitalis Could Be Safe In Diastolic Heart Failure 3
Very compressive support for submental liposuction...
Applies pressure on scalp to stretch it before surgery...
Deluxe Abdominal Binders...
Ideal for abdominal, flank, hip and thigh procedures....
Medicine Products: